Correction of albendazole disease after echinococcectomy of the liver
|
|
Author:
|
, KOSIM E. RAKHMANOV, SALIM S. DAVLATOV, DIYOR SH. ABDURAXMANOV
|
Abstract:
|
The purpose of the study. Improving the quality of treatment of patients with liver echinococcosis by optimizing postoperative chemotherapy. Research materials. The study is based on the results of treatment of 226 patients with liver echinococcosis who were admitted to the surgical Department of the Samarkand state medical Institute, 2nd clinic during the period of 2009-2017. Patients were divided into two groups: from 2009 to 2012, 112 (49.5%) patients who made up the comparison group were operated on, and from 2013 to 2017, 114 (50.5%) patients who were included in the main group, were under our supervision. In the comparison group, postoperative chemotherapy was performed according to the traditional scheme. In the main group, the dose of albendazole was adjusted taking into account the functional initial state of the liver. In verified chronic liver disease, as well as in cases with an initial (before surgery) increase in liver enzymes basing on the positive results of the experimental study, albendazole was used at the dosage of 5 mg/kg/day. Results of the study. The probability of developing adverse reactions against the background of chemotherapy with albendazole according to clinical and laboratory parameters was 52.7%, which is due to the toxic effect of the drug and the presence of concomitant chronic diffuse liver pathology. In turn, the possibility of dose adjustment allowed to reduce this value up to 18.3%. Conclusions. Dose adjustment in patients with adverse events contributed to the normalization of biochemical parameters and reduced the risk of toxic manifestations during chemotherapy. The recurrence of echinococcosis was noted in 6 (4.2%) patients, out of 144 patients examined in the long term.
|
Keyword:
|
Echinococcosis of the liver, prophylaxis of recurrence, chemotherapy, albendazole.
|
EOI:
|
-
|
DOI:
|
https://doi.org/10.31838/ijpr/2021.13.01.596
|
Download:
|
Request For Article
|
|
|